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Editorial
The importance of cumulative meta-analyses and implications for B-type 
natriuretic peptide research in non-cardiac surgery
It is a travesty to waste resources. In medicine, a persistence of 
futile research depletes the already limited resources available 
for research. Furthermore, ignoring clinical trial evidence of 
benefit is unethical and negatively impacts on public health. 
Cumulative meta-analyses have contributed substantially to 
limiting waste in research. A cumulative meta-analysis provides 
a “running total” of the overall effect for an intervention through 
sequentially adding each published trial (or study) to an 
ongoing meta-analysis. This technique led to an appreciation 
of the significant delay from the time that clinical trials show 
unequivocal benefit of a treatment, to subsequent awareness 
of this benefit by practising clinicians. The turning point was 
a cumulative meta-analysis of the use of oral beta blockers for 
the secondary prevention of mortality following myocardial 
infarction (MI). As early as 1977, there was sufficient evidence of a 
survival benefit, with only 3 522 patients randomised.1,2 However, 
clinical trials continued for a further 10 years, and 17 000 more 
patients were randomised prior to an appreciation of the 
evidence supporting this indication for beta blockers.1,2 This 
situation has major negative public health implications. Firstly, 
patients are randomised into trials where the benefit should be 
known. Hence, the placebo group is essentially randomised to 
harm as they are denied efficacious therapy. Secondly, the public 
and population are denied the benefit of the therapy, despite 
evidence to support its use. In this example, patients with an MI 
over a period of 10 years were denied therapy associated with a 
relative risk reduction in subsequent mortality of approximately 
20%.1,2 It is now standard practice to present a systematic review 
when applying for a grant for an interventional clinical trial 
because of these startling facts. This prevents wasteful clinical 
trials from being conducted in the presence of sufficient existing 
evidence of efficacy.
However, it is not standard practice to present a meta-analysis 
prior to conducting an observational study. The work by Ryan et 
al, presented in this edition of SAJAA,3 supports the important 
public health contribution that a cumulative meta-analysis may 
play in observational studies. They may identify a time when 
it is appropriate to shift the research focus. The point estimate 
associated with an adverse cardiovascular outcome in non-
cardiac surgery for elevated B-type natriuretic peptides (BNPs) 
has been fairly consistent since 2011.3 Therefore, it is wasteful 
to persist in this line of observational research. Rather, a shift is 
needed in preoperative BNP research from merely documenting 
its prognostic importance addressing its integration into clinical 
practice. 
Preoperative BNP research has fulfilled the first four of the six 
progressive stages of evaluation necessary before BNP can 
be adopted in preoperative cardiac evaluation guidelines 
and algorithms.4 Proof of concept, prospective validation, 
incremental value and clinical utility have been demonstrated.5 
It is now time to demonstrate that the modification of 
perioperative management, based on preoperative BNP, 
improves perioperative outcomes (stage 5). If this can be 
achieved, and only if it is cost-effective (stage 6), it is likely that 
preoperative BNPs will be written into perioperative clinical 
guidelines.4 The most important candidate study to achieve this 
objective would be a prospective, multi-centred, randomised 
trial of preoperative BNP-guided medical optimisation, to 
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